Craig Maxwell joins JPMorgan to co-head pharmaceutical equity research team in London
10/11/04 - PRNewswire
London, October 1 /PRNewswire/ -- - Total of three to join team JPMorgan "We are delighted to have professionals with such outstanding investor relationships and valuable knowledge of the industry," said Peter Redhead, head of Equity Research for EMEA at JPMorgan. "The team will lead coverage of European companies, providing premier analysis for investors within a global context." The global pharmaceuticals equity research team is led by Carl Seiden who is based in New York and is head of JPMorgan's U.S. pharmaceutical team. Over the past five years the team has ranked consistently high in Institutional Investor's surveys, with a number one ranking in 2002. Maxwell joins JPMorgan from Bank of America. Previously, he spent over ten years in the industry at Glaxo Smithkline Beecham and Merck Sharp and Dohme. Patel was based in New York with JPMorgan's U.S. pharmaceutical team. Also joining the team is Justin Smith from Citigroup Smith Barney and Keyer Parekh from Credit Suisse First Boston (CSFB). J.P. Morgan Chase & Co. is a leading global financial services firm with assets of US$803 billion and operations in more than 50 countries. The firm is a leader in investment banking, asset management, private banking, private equity, custody and transaction services, and retail and middle market financial services. A component of the Dow Jones Industrial Average, JPMorgan Chase is headquartered in New York and serves more than 30 million consumer customers and the world's most prominent corporate, institutional and government clients. Information about JPMorgan Chase is available on the internet at http://www.jpmorganchase.com/. (press) Sarah Oppler, tel +44 (0)20-7325-3644 or email
News